4月7日 - ** 生物技术公司Plus Therapeutics PSTV.O股价盘前上涨3.6%至3.45美元
** 该公司称美国医学协会批准了其CNSide检测的新计费代码，自2026年7月1日起生效
** CNSide 用于检测癌症已扩散到大脑和脊髓的患者脊髓液中的癌细胞，这是一种严重且通常难以诊断的疾病 - PSTV
** 该公司表示，新代码将使医生和医院更容易向保险公司报销费用，从而支持更广泛地使用该检测方法。
** 该公司称，该批准标志着其诊断业务在美国的商业推广迈出了关键一步
** 截至上一交易日收盘，股价年累计下跌约 21%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.